Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol Intoxication

CompletedOBSERVATIONAL
Enrollment

296

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

November 1, 2024

Study Completion Date

February 28, 2025

Conditions
Ethanol Intoxication
Interventions
DRUG

Reamberin

Reamberin® in the average daily dose of 10 ml/kg daily

Trial Locations (18)

Unknown

City Clinical Hospital of Emergency Medical Care, Kaliningrad

K.N. Shevchenko Kaluga Regional Clinical Hospital of Emergency Medical Care, Kaluga

M.A. Podgorbunsky Kuzbass Clinical Hospital of Emergency Medical Care, Kuzbass

Buyanov City Clinical Hospital, Moscow

KORSAKOV Medical Center, Moscow

N.V. Sklifosovsky Research Institute of Emergency Care of the Moscow City Health Department, Moscow

Negovsky Research Institute of General Intensive Care Medicine, Moscow

Zhukovskaya City Clinical Hospital, Moscow

City Clinical Hospital No. 2, Novosibirsk

City Clinical Hospital of Emergency Medicine No. 1, Omsk

Regional Clinical Hospital,, Ryazan

City Mariinskaya Hospital, Saint Petersburg

City Narcological Hospital, Saint Petersburg

Dzhanelidze St. Petersburg Research Institute of Emergency Medicine, Saint Petersburg

State Healthcare Institution Saratov Yu. Ya. Gordeev City Clinical Hospital No. 1, Saratov

V.N. Koshelev City Clinical Hospital No. 6, Saratov

Tyumen State Medical University, Tyumen

Yaroslavl Regional Clinical Narcological Hospital, Yaroslavl

All Listed Sponsors
lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY